Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose, Precedent of Compass Bill; VA Loses Psychedelics Champion; GH Discusses Lack of Placebo Effect
- Q4’24: Federal Psychedelics Lobbying Update
- Drug Developers
- Nonprofits
- Psychedelic Lobbying Under Trump
- GH Research Discusses Lack of Placebo Effect, Decision to Keep Trial Sites Secret
- Virginia Lawmakers Question Purpose and Precedent of Compass’ Rescheduling Bill
- Other Stories
- VA Psychedelics Champion Leaves Post
- Colorado’s Psychedelics Program Sees Slow Start
- Lykos’ FDA Rejection in Context
- Center for MINDS Backs Psilocybin for Creativity Study
- Study Reveals Differing Views on Psychological Support
- More Headlines
Q4’24: Federal Psychedelics Lobbying Update
Q4 2024 lobbying disclosure forms have now been filed, so we are taking a quick look at updates since our last review.
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In